Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026

The pipeline VLR199 (the lead candidate): works in the same way as sotatercept (Winrevair), by trapping proteins of the activin family that drive the abnormal growth of cells in the lung vessels. The aim is to improve on aspects of sotatercept that may not be “fully optimised”. First clinical results showing whether it works are […]

Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026 Read Post »

Evolving profile and outcomes of patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation in France, Journal of Heart and Lung Transplant, September 3, 2026

A study published in Journal of Heart and Lung Transplant Open by a large French team looked at all 241 patients with pulmonary arterial hypertension who had a lung or heart-lung transplant in France between 2008 and 2023. Using data from the national registries for the disease and for transplants, the authors compared two periods:

Evolving profile and outcomes of patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation in France, Journal of Heart and Lung Transplant, September 3, 2026 Read Post »

What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026

September was a busy month in the pulmonary hypertension world, with the European Society of Cardiology (ESC) and European Respiratory Society Congresses (ERS) bringing a wave of new research. The most important news is the update of the ERS Clinical Practice Guidelines for the treatment of pulmonary arterial hypertension (PAH), presented in Barcelona. AfPH Vice

What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026 Read Post »

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension

Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension and Chair of the Dutch pulmonary hypertension foundation, attended both the European Society of Cardiology and the European Respiratory Society (ERS) Annual Congresses 2026 taking place respectively in Munich, Germany (August 28-30), and Barcelona, Spain (September 5-9). Based on the sessions she followed, she has

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension Read Post »

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026

We are thrilled to release five brand-new “Patients Empowering Patients” talks — five women, three countries (Italy, Turkey, the US), and five very different stories, all united by the same resilience and positive outlook that defines this community. From Aygün Mengelli Tomur’s lung transplant journey “From Waiting to Breathing: A New Beginning,” to Deger Kesimogluğlu’s

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026 Read Post »

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026

The French Pulmonary Hypertension Association HTaPFrance is holding its 6th Patient Congress, 13–15 November 2026 at Centre Valpré in Écully, France — coinciding with the association’s 30th anniversary. The congress is open to pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH patients, those awaiting or having received a transplant, along with their families,

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026 Read Post »

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available

A live, case-based webinar held on June 2, 2026 looked at when and how patients with advanced pulmonary disease should be referred for lung transplant evaluation. The expert faculty walked through evidence-based referral criteria, disease-specific considerations, and complex scenarios — including interstitial lung disease, pulmonary arterial hypertension, and critically ill patients in the Intensive Care

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available Read Post »

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026

Over the past 40 years, treatment for pulmonary arterial hypertension (PAH) has changed dramatically. What was once considered a disease with very few treatment options is now managed with a growing range of therapies that help people live longer and enjoy a better quality of life. A review recently published in Circulation looks back at

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026 Read Post »

Patient advocate Natalia Maeva at the European Respiratory Society (ERS) Presidential Summit, Warsaw 2026

Natalia Maeva, a patient advocate for pulmonary hypertension, attended the European Respiratory Society (ERS) Presidential Summit in Warsaw in June 2026, participating in sessions on early detection, air quality, tobacco control, climate change and lung health. Having had her own life transformed by access to specialised treatment and lung transplantation, she found the discussions on

Patient advocate Natalia Maeva at the European Respiratory Society (ERS) Presidential Summit, Warsaw 2026 Read Post »

Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition

Bronchiolitis obliterans syndrome (BOS) is the most common form of chronic lung allograft dysfunction after lung transplant, marked by progressive small airway disease with limited treatment options. This case report describes a 55-year-old woman with primary ciliary dyskinesia, post-bilateral lung transplant, who developed severe (stage 3) bronchiolitis obliterans syndrome and went into respiratory failure requiring

Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition Read Post »

What’s new in pulmonary hypertension on the Knowldge Sharing Platform, May 2026

This month’s selection reflects the remarkable momentum in the pulmonary hypertension field — from landmark regulatory approvals and cutting-edge research to inspiring human stories and practical tools for patients. As always, we have curated a range of content to inform, inspire, and empower our community. RESEARCH AND SCIENCE INDUSTRY NEWS DIGITAL HEALTH AND INNOVATION TRANSPLANT

What’s new in pulmonary hypertension on the Knowldge Sharing Platform, May 2026 Read Post »

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026

Welcome to our April roundup of the most relevant and interesting content shared on this platform. April 2026 has been a particularly rich month, with significant news on the diagnostics, clinical trials and treatment front alongside important research on quality of life, patient preferences information, economic burden. There is also a selection of patient resources

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026 Read Post »

The latest edition of “Connections”, the Canadian Pulmonary Hypertension Association (PHA Canada)’s twice-yearly magazine, is dedicated to raising awareness of organ donation and transplant

This month, The Canadian Pulmonary Hypertension Association PHA Canada is raising awareness about the life-changing impact of organ and tissue donation. The newest issue of their magazine Connections is dedicated to Transplant & Pulmonary Hypertension, and it explores this important topic through stories, insights, and resources from the community. 👉 Subscribe to Connections and receive

The latest edition of “Connections”, the Canadian Pulmonary Hypertension Association (PHA Canada)’s twice-yearly magazine, is dedicated to raising awareness of organ donation and transplant Read Post »

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026

This review covers the full clinical picture of pulmonary arterial hypertension (PAH) — from its pathophysiology and diagnosis through to current and emerging treatments. Understanding the Disease Pulmonary arterial hypertension is driven by progressive structural remodelling of the pulmonary arteries, creating a vicious cycle of vasoconstriction, inflammation, and uncontrolled cell growth that ultimately leads to

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026 Read Post »

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants!

The Alliance for Pulmonary Hypertension (AfPH) recently concluded its 14th webinar, marking the culmination of an educational initiative that began in June 2023. These virtual gatherings brought together internationally renowned experts in pulmonary hypertension, who shared their expertise on a comprehensive range of topics crucial to advancing patient care and quality of life. The diverse

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants! Read Post »

The “Pulmonary Hypertension Global Patient and Carer Survey” (PH GPS) is launched, October 16, 2023

This survey, the first of its kind, has been designed to help improve global understandings of how pulmonary hypertension affects the lives of patients and in what ways pulmonary hypertension care needs to be improved. The survey has been written by a multidisciplinary panel of pulmonary hypertension specialists and patient group advocates from the pulmonary

The “Pulmonary Hypertension Global Patient and Carer Survey” (PH GPS) is launched, October 16, 2023 Read Post »

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages

Did you know that the lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages: English, French, German, Greek, Italian, Polish, Portuguese (Portugal), Russian, Spanish, Romanian, Ukrainian. The English version of the lay summary was developed with the active collaboration of the two

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages Read Post »

Lay summary of the 2022 ESC/ERS clinical guidelines on the diagnosis and treatment of pulmonary hypertension now available in 11 languages!

“Diagnosing and treating pulmonary hypertension – understanding the professional guidelines” is an easy to understand summary of the joint European Society of Cardiology (ESC) and European Respiratory Society (ERS) clinical guidelines for pulmonary hypertension (PH). It was published on the European Lung Foundation (ELF) website on 02/11/2022. It is for people with pulmonary hypertension, or

Lay summary of the 2022 ESC/ERS clinical guidelines on the diagnosis and treatment of pulmonary hypertension now available in 11 languages! Read Post »

PHA UK’s “sister” website, phocusonlifestyle.org, is addressed at patients and caregivers and houses a wealth of support resources and pulmonary hypertension patient stories

http://www.phocusonlifestyle.org is the “sister” website to that of the UK Pulmonary Hypertension, PHA UK. It is aimed at patients and peers supporting each other through stories. It also houses written resources covering a very wide range of issues related to living with pulmonary hypertension including:

PHA UK’s “sister” website, phocusonlifestyle.org, is addressed at patients and caregivers and houses a wealth of support resources and pulmonary hypertension patient stories Read Post »

The 2022 “Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension” by the European Society of Cardiology (ESC) and European Respiratory Society (ERS)

The work of two years of the Task Force in charge of the new European Society of Cardiology (ESC) and European Respiratory Society (ERS) joint Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension has finally come to an end. The new guidelines were officially presented yesterday at the ESC Annual Congress in Barcelona

The 2022 “Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension” by the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Read Post »

TRANSLATE »
Scroll to Top